EUVIMEDEUVIMED entdecken
Crossref

Lerodalcibep (Lerochol) for Hypercholesterolemia

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 71-75

DOI: 10.58347/tml.2026.1754a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved lerodalcibep (Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is the fourth subcutaneously injected PCSK9-directed therapy to be approved in the US; the monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and the small interfering RNA inclisiran (Leqvio) were approved earlier.

Schlagwörter

Stichwörter der Autor:innen

LeqvioLerocholNexletolPraluentRepathaZetiaadverse effectsalirocumabbempedoic aciddosageefficacyevolocumabezetimibehypercholesterolemiainclisiran

Zitieren

APA

(2026). Lerodalcibep (Lerochol) for Hypercholesterolemia. The Medical Letter on Drugs and Therapeutics, 68(1754), 71-75. https://doi.org/10.58347/tml.2026.1754a

Vancouver

Lerodalcibep (Lerochol) for Hypercholesterolemia. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):71-75. doi:10.58347/tml.2026.1754a

BibTeX
@article{euvimed2026,
  title = {Lerodalcibep (Lerochol) for Hypercholesterolemia},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {71--75},
  doi = {10.58347/tml.2026.1754a}
}
Kostenlos starten →